Bellicum Appoints Jim Daly to its Board of Directors
“We are pleased to welcome an executive with Jim’s extensive senior
leadership experience to our Board of Directors,” said
Most recently, Mr. Daly served as Executive Vice President and Chief
Commercial Officer at
Earlier in his career, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair®.
Mr. Daly earned a B.S. in Pharmacy and an M.B.A. from the
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Bellicum may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue," “designed,”
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, or current expectations
concerning, among other things, our research and development activities
relating to the advancement and potential commercialization of our
products under development. Various factors may cause differences
between Bellicum’s expectations and actual results as discussed in
greater detail under the heading “Risk Factors” in Bellicum’s filings